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Abstract: The neglected tropical diseases (NTDs) are the
most common conditions affecting the poorest 500
million people living in sub-Saharan Africa (SSA), and
together produce a burden of disease that may be
equivalent to up to one-half of SSA’s malaria disease
burden and more than double that caused by tubercu-
losis. Approximately 85% of the NTD disease burden
results from helminth infections. Hookworm infection
occurs in almost half of SSA’s poorest people, including
40–50 million school-aged children and 7 million preg-
nant women in whom it is a leading cause of anemia.
Schistosomiasis is the second most prevalent NTD after
hookworm (192 million cases), accounting for 93% of the
world’s number of cases and possibly associated with
increased horizontal transmission of HIV/AIDS. Lymphatic
filariasis (46–51 million cases) and onchocerciasis (37
million cases) are also widespread in SSA, each disease
representing a significant cause of disability and reduction
in the region’s agricultural productivity. There is a dearth
of information on Africa’s non-helminth NTDs. The
protozoan infections, human African trypanosomiasis
and visceral leishmaniasis, affect almost 100,000 people,
primarily in areas of conflict in SSA where they cause high
mortality, and where trachoma is the most prevalent
bacterial NTD (30 million cases). However, there are little
or no data on some very important protozoan infections,
e.g., amebiasis and toxoplasmosis; bacterial infections,
e.g., typhoid fever and non-typhoidal salmonellosis, the
tick-borne bacterial zoonoses, and non-tuberculosis my-
cobaterial infections; and arboviral infections. Thus, the
overall burden of Africa’s NTDs may be severely under-
estimated. A full assessment is an important step for
disease control priorities, particularly in Nigeria and the
Democratic Republic of Congo, where the greatest
number of NTDs may occur.
Introduction
The neglected tropical diseases (NTDs) are a group of chronic,
disabling, and disfiguring conditions that occur most commonly in
the setting of extreme poverty, especially among the rural poor and
some disadvantaged urban populations [1]. Today, the world’s
greatest concentration of poverty occurs in sub-Saharan Africa (SSA).
According to a recent World Bank analysis, 51% of the population of
SSA lives on less than US$1.25 per day, and 73% of the population
lives on less than US$2 per day (Table1) [2]. Previous studies indicate
that the NTDs are widespread among the poor in SSA [3–6], with
the most common NTDs, such as the soil-transmitted helminth
(STH) infections, schistosomiasis, lymphatic filariasis (LF), trachoma,
and onchocerciasis together affecting more than 500 million people
[3,6–8]. Because of their adverse effects on child development,
pregnancy outcome, and agricultural worker productivity [1,3,6,7,9–
17], the NTDs represent a major reason why the ‘‘bottom 500
million’’ people in SSA cannot escape poverty. Therefore, new and
ongoing efforts to control and eliminate the NTDs represent key
elements for achieving Africa’s Millennium Development Goals
(MDGs) for sustainable poverty reduction, including the MDGs to
eradicate poverty (MDG 1), promote education (MDG 2), reduce
child mortality (MDG 4), improve maternal health (MDG 5), and to
combat ‘‘other diseases’’ (MDG 6) [1,7,8].
Specific information on the prevalence, distribution, and disease
burden resulting from the NTDs in SSA would provide a basis for
prioritizing control strategies as a means to address the MDGs.
Over the last decade, geographic information systems (GIS) and
remote sensing (RS) have facilitated a deeper understanding of the
prevalence and distribution of NTDs, particularly for helminth
infections in SSA [4,5,18–21]. Simultaneously, a fresh assessment
of the chronic and subtle morbidities caused by NTDs has
highlighted a previously underappreciated disease burden [22,23].
Here, we review current knowledge on the prevalence, distribu-
tion, and disease burden resulting from NTDs in SSA, focusing on
aspects particular to the region. The review of the literature was
conducted using the online database PubMed from 2003 to 2008
with the Medical Subject Headings (MeSH), the specific diseases
listed as neglected tropical diseases on the PLoS Neglected Tropical
Disease Web site (http://www.plosntds.org/static/scope.action),
and the geographic regions and countries of SSA. Reference lists
of identified articles and reviews were also hand searched as were
databases from the World Health Organization (WHO, http://
www.who.int), including the WHO’s Weekly Epidemiological Record.
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Table 2 ranks the major NTDs in SSA by their estimated
prevalence, the percentage of the population infected, and the
percentage of the world’s cases found in the region, while Table 3
ranks the countries with the highest prevalence of each of the
NTDs. Helminth infections, especially the STH infections,
schistosomiasis, and the filarial infections LF and onchocerciasis,
are the most common NTDs in SSA, followed by trachoma and
other bacterial infections [3,21–38]. Human African trypanoso-
miasis (HAT) and leishmaniasis are the most common serious
protozoan infections, especially in areas of conflict where these
diseases emerge in the setting of inadequate housing and forced
migrations [39–44]. However, as shown in Table 4, there are
more than a dozen important NTDs, including the protozoan
infections, amebiasis and toxoplasmosis; bacterial infections such
as Salmonella infections (both typhoid fever and non-typhoidal
salmonellosis), the tick-borne zoonoses, and yaws; and viral
infections such as Rift Valley fever, for which there is insufficient
information available in order to estimate their prevalence in
SSA. Based on global disease burden estimates in disability-
adjusted life years (DALYs) published previously by the WHO
and other investigators [3,35,45–48], a range of estimates for the
NTDs in SSA is provided in Table 5. DALY estimates for the
STH infections and schistosomiasis were obtained by adjusting a
wide range of available global estimates according to the
percentage of the total number of cases that occur in SSA,
while for the other NTDs the disease burdens were quoted
directly from WHO estimates. From this analysis it was
determined that the total burden of NTDs in SSA is possibly
as high as one-half the disease burden caused by malaria and
twice the disease burden caused by tuberculosis in SSA (Table 6),
suggesting that the NTDs represent a formidable public health
challenge in the region. Up to 85% of the NTD disease burden
specifically results from helminth infections (Table 6). However,
even this high disease burden resulting from helminth infections
and other NTDs may represent an underestimate because they
do not incorporate the full spectrum of chronic sequelae [22,23],
and because such estimates do not include NTDs listed in
Table 4.
Helminth Infections
STH infections (hookworm infection, ascariasis,
trichuriasis). Since the global prevalence of STH infections
was first estimated by Stoll over 60 years ago [31], the overall
prevalence of the STH infections is believed to have remained
relatively constant in SSA, whereas it has diminished elsewhere in
the developing world [24]. Today, between one-quarter and one-
third of SSA’s population is affected by one or more STH
infections [24], with children, especially school-aged children,
disproportionately affected. Of the estimated 181 million school-
Table 1. Poverty in Sub-Saharan Africa.
Percentage of SSA population living on less than
US$1.25 per day
51%
Total SSA population living on less than $1.25 per
day
390.6 million
Percentage of world’s population living on less than
US$1.25 per day in SSA
28%
Percentage of SSA population living on less than
US$2 per day
73%
Total SSA population living on less than $2 per day 556.7 million
Percentage of world’s population living on less than
US$2 per day in SSA
22%
From reference [2].
doi:10.1371/journal.pntd.0000412.t001
Table 2. Ranking of Neglected Tropical Diseases (NTDs) in SSA by Prevalence and Distribution.
Disease
Estimated Population
Infected in SSA
Estimated % of SSA
Population Infected
Estimated % Global Disease
Burden in SSA Reference
Hookworm 198 million 29%
a 34%
b [3,24]
Schistosomiasis 192 million 25% 93% [21]
Ascariasis 173 million 25%a 21%
2b [3,24]
Trichuriasis 162 million 24%
a 27%
b [3,24]
Lymphatic filariasis 46–51 million 6%–9% 37%–44%
c [25–28]
Onchocerciasis 37 million 5% .99% [15,29]
Active trachoma 30 million 3% 48% [30]
Loiasis #13 million 1%–2% 100% [31,32]
Yellow fever 180,000 0.02% 90% [33,34]
Human African trypanosomiasis 50,000–70,000 (17,000 new cases
annually)
,0.01% 100% [39,40]
Leprosy 30,055 (registered prevalence);
21,037 new cases in 2007
,0.01% 14% [35]
Leishmaniasis (visceral) 19,000–24,000 new cases annually
in Sudan and Ethiopia
,0.01 ND [41–44]
Dracunculiasis 9,585 ,0.01% 100% [36]
Buruli ulcer .4,000 ,0.01% 57% [37,38]
aBased on reported 2003 population of 683,330,334 [24]. For all other estimated population prevalence, we use the 2005 value of 764,328,000 published by the United
Nations, http://esa.un.org/unpp/, and querying sub-Saharan Africa and 2005, accessed July 29, 2009.
bCalculated from global burden data from [48].
cThe lower value is from [3,26,27]; the higher value from [25].
doi:10.1371/journal.pntd.0000412.t002
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with hookworm, ascariasis, trichuriasis, or some combination of
these STH infections [4]. Typically, children exhibit higher STH
intensities than any other single population [4] and as a result
suffer from profound physical and mental deficits [6,10,49–51].
Such deficits partially account for their high disease burden in
SSA. Moreover, in Kenya (and presumably elsewhere), these
effects also translate into increases in school absenteeism and
reduced school performance [14].
Hookworm infection (‘‘hookworm’’). Hookworm is the most common
STH infection and the most common NTD in SSA (Tables 2 and
3). It is also one of the most important in terms of disease burden,
accounting for up to one-third of the total burden from NTDs in
SSA (Table 5). Based on previous estimates derived in 2002 [24], it
is estimated that 198 million people in SSA are infected with
hookworm (29% of the region’s population), including 40–50
million school-aged children [4,5]. Approximately one-third of the
world’s hookworm today occurs in SSA (Table 2) [3], with the
greatest number of cases occurring in Nigeria (38 million) and the
Democratic Republic of Congo (DRC, 31 million), followed by
Angola, Ethiopia, and Cote d’Ivoire (10–11 million) (Table 3).
Hookworm is the most widely distributed NTD in SSA and it is
pervasive throughout the region (including both rural and urban
areas) except in some parts of extreme southern Africa [4,5]. Two
areas are particularly notable for their high hookworm prevalence
and intensity compared to other helminth infections, namely
coastal regions [52], and areas of extremely high temperatures
(where land surface temperatures exceed 37–40uC), including
those near the Sahel such as Cameroon [18], Chad [19], and Mali
[53,54]. Through GIS/RS such information can be used to
generate predictive maps of areas of high hookworm prevalence as
well as their geographic overlap with potential co-infections [4,5].
For instance, it is estimated that approximately 90% of the 50
million school-aged children with hookworm are at risk for
coincident co-infection with falciparum malaria [5,55]. Both
Necator americanus and Ancylostoma duodenale are found in SSA, with
the former representing the predominant hookworm species [56].
Because they cause intestinal blood loss, hookworm is a leading
cause of iron deficiency anemia in the region [57]. Among school-
aged children in Zanzibar, 35% of iron deficiency anemia and
73% of severe anemia was attributable to hookworm [58], while in
Kenya and elsewhere in Africa, hookworm also is an important
cause of anemia among preschool children [59,60]. Hookworm
has also been recognized as an important cause of anemia and
morbidity in women of reproductive age in SSA, especially among
pregnant women [57,61]. At any given time, almost 7 million
pregnant women in SSA (up to one-third of pregnant women in
the region) are infected with hookworm [17]. Hookworm’s high
disease burden in SSA reflects its importance as a cause of
maternal and child anemia (Table 5).
Ascariasis and trichuriasis. The highest intensity Ascaris and Trichuris
infections occur in school-aged children [4]. It is estimated that
173 million and 162 million people are infected in SSA with Ascaris
and Trichuris, respectively, with 36 million school-aged children
infected with ascariasis and 44 million with trichuriasis [4]. For
both infections the largest number of cases occurs in Nigeria,
where co-infections with hookworm are common [62]. Tens of
millions of cases are also found in Ethiopia, DRC, and South
Africa (Table 3). Compared to hookworm, both ascariasis and
trichuriasis exhibit a more patchy distribution in SSA, with the
highest prevalence occurring in equatorial Central and West
Africa, eastern Madagascar, and southeast Africa [4]. In contrast
to the high rates of ascariasis and trichuriasis in South Africa
[63,64], hookworm is less common except in KwaZulu-Natal [52].
Moreover, higher prevalence rates of ascariasis and trichuriasis are
often present in Africa’s urban areas compared to rural areas,
unlike hookworm, which is more evenly distributed [4]. These
observations may reflect the ability of Ascaris and Trichuris eggs to
Table 3. Geographic Distribution and Estimated Burden of the Major Helminth NTDs in SSA.
Disease (Number of
Cases in SSA)
Country with Highest
Prevalence
Country with Second
Highest Prevalence
Country with Third Highest
Prevalence
Country with Fourth
Highest Prevalence Reference
Hookworm infection
(198 million)
Nigeria 38 million DR Congo 31 million Angola and Ethiopia 11 million
cases each
Cote d’Ivoire 10 million [24]
Schistosomiasis
(192 million)
Nigeria 29 million Tanzania 19 million DR Congo and Ghana 15
million cases each
Mozambique 13 million [21]
Ascariasis (173 million) Nigeria 55 million Ethiopia 26 million DR Congo 23 million South Africa 12 million [24]
Trichuriasis (162 million) Nigeria 34 million DR Congo 26 million South Africa 22 million Ethiopia 21 million [24]
Lymphatic filariasis
(382–394 million at risk)
Nigeria 106 million at risk DR Congo 49 million
at risk
Tanzania 31 million at risk Ethiopia 30 million at risk,
Kenya 29 million at risk
[28]
Trachoma (30 million) Ethiopia 10.3 million Sudan 3.6 million Tanzania 2.1 million Kenya and Niger 2.0
million cases each
[30]
Yellow fever (180,000) Cote d’Ivoire 16 reported
cases in 2006
Mali 5 reported cases
in 2006
Cameroon, CAR, Ghana, and
Guinea 1 case each in 2006
[33,34]
Human African trypanoso-
miasis (50,000–70,000)
DR Congo 10,369 Angola 2,280 Sudan 1,766 Congo 839 [39]
Leprosy (30,055) DR Congo 6,502 Nigeria 5,381 Ethiopia 4,611 Mozambique 1,830 [35]
Leishmaniasis (visceral)
(19,000–24,000 new cases)
Sudan 15,000–20,000 new
cases
Ethiopia 4,000 new
cases
Kenya and Uganda not
determined
[41–44]
Dracunculiasis (9,585) Sudan 5,815 Ghana 3,358 Mali 313 Nigeria and Niger,100
cases each
[36]
Buruli ulcer (.4,000) Cote d’Ivoire 2,000 Benin and Ghana
1,000 each
[37]
doi:10.1371/journal.pntd.0000412.t003
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SSA may promote emergence of ascariasis and trichuriasis in the
future.
Other STH infections. Strongyloidiasis causes diarrhea and
malnutrition in SSA, although there is little information on its
distribution or disease burden (Table 4), in part because of the
difficulties in diagnosing this infection. In one study,
strongyloidiasis accounted for 5.3% of diarrhea in malnourished
Nigerian children [65]. Two other intestinal nematode infections
are focally endemic. Oesophagostomum bifurcum is common in
northern Ghana and Togo [66], and Ternidens deminutus (the
‘‘false hookworm’’) occurs in Zimbabwe [67].
Schistosomiasis and other platyhelminthiases. Of the
world’s 207 million estimated cases of schistosomiasis, 93% occur
in SSA (192 million) (Table 2), with the largest number in Nigeria
(29 million) followed by United Republic of Tanzania (19 million),
and DRC and Ghana (15 million each) [21] (Table 3).
Approximately 76% of the population in SSA lives near rivers,
lakes, and other water bodies contaminated with snail
intermediate hosts [21,68–70]. Those living near dam reservoirs
are at particular risk [21], and SSA has several examples where the
infection has emerged or where there has been a dramatic rise in
the prevalence of schistosomiasis as a result of irrigation project
construction [21,71]. Climate change and global warming may
also be factors [72].
The highest prevalence and intensities of human schistosomiasis
occur in school-aged children, adolescents, and young adults who
also suffer from the highest morbidity and mortality. There are
two major forms of schistosomiasis found in SSA. Approximately
two-thirds of the schistosomiasis cases are due to infection caused
by Schistosoma haematobium, which represents an important cause of
severe urinary tract disease [73]. In 2000, van der Werf et al.
estimated that 70 million and 32 million individuals out of 682
million people in SSA had experienced hematuria and dysuria,
respectively, within the last two weeks [73]. S. haematobium
produces bladder wall pathology in approximately 18 million
people in SSA, and 10 million people suffer from hydronephrosis
[73]. Renal failure accounts for a large percentage of the estimated
150,000 deaths from urinary tract schistosomiasis in SSA, and
there is also a significant association between major bladder wall
pathology and squamous cell carcinoma [74]. A significant
percentage of women and men with urinary schistosomiasis
acquire genital ulcers and other lesions [22]. In the former,
urogenital schistosomiasis is a significant cause of poor reproduc-
tive health, including sexual dysfunction and infertility [75].
Genital schistosomiasis also promotes the horizontal transmission
of HIV/AIDS in SSA [76]. Intestinal schistosomiasis from S.
mansoni causes most of the remaining cases in SSA. An estimated
4.4 million people with S. mansoni have bloody diarrhea and bowel
ulceration, and 8.5 million develop hepatomegaly and/or
Table 4. Major NTDs with No Regional Prevalence or Incidence Estimates in SSA.
Helminth Infections Protozoan Infections Bacterial Infections Viral Infections Other Conditions
Strongyloidiasis Amebiasis Bovine tuberculosis Dengue fever Podoconiosis
Taeniaisis Toxoplasmosis Tick-borne relapsing fever Rift Valley fever
Paragonimiasis African tick-bite fever Chikungunya
Oesophagostomiasis Typhoid fever Rabies
Non-typhoidal salmonellosis
Yaws
doi:10.1371/journal.pntd.0000412.t004
Table 5. Disease Burden (DALYs) in SSA Resulting from the NTDs.
Disease
Estimated Global Disease
Burden in DALYs
Estimated % Disease
Burden in SSA
Estimated SSA Disease
Burden in DALYs Reference
Hookworm 1.5–22.1 million 34% 0.5–7.5 million [46–48]
Schistosomiasis 1.7–4.5 million 93% 1.6–4.2 million [21,45,47]
Ascariasis 1.8–10.5 million 21% 0.4–2.2 million [46–48]
Lymphatic filariasis 5.8 million 35% 2.0 million [45]
Trichuriasis 1.8–6.4 million 27% 0.5–1.7 million [46–48]
Human African trypanosomiasis 1.5 million 100% 1.5 million [45]
Trachoma 2.3 million 52% 1.2 million [45]
Onchocerciasis 0.5 million 99% 0.5 million [45]
Leishmaniasis 2.1 million 18% 0.4 million [45]
Leprosy 0.2 million 14% 0.02 million [35,45]
Dengue 0.6 million ,1% 0.005 million [45]
Total NTDs #56.6 million 15%–37% 8.6 million–21.2 million [47]
DALY estimates for STH infections and schistosomiasis were obtained by adjusting a wide range of available global estimates according to the percentage of the total
number of cases that occur in SSA, while for the other NTDs the disease burdens were quoted directly from WHO estimates.
doi:10.1371/journal.pntd.0000412.t005
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hematemesis from S. mansoni infection, with approximately
130,000 deaths [22,73]. S. intercalatum causes a second form of
intestinal schistosomiasis, but with a restricted distribution in West
and Central Africa [77].
In addition to the organ-specific pathology described for both S.
haematobium and S. mansoni infections, there is increasing evidence
for more generalized morbidity resulting from the chronic
inflammation of these long-standing infections [22,23]. Among
the most important are anemia of chronic inflammation and iron
deficiency anemia, growth stunting and malnutrition, fatigue and
diminished physical fitness, and impaired cognitive development
[22,23]. The current disease burden calculations for schistosomi-
asis range between 1.7 and 4.5 million DALYs lost annually (1.6
and 4.2 million DALYs in SSA) (Table 5), but these current
estimates do not fully consider the general morbidities outlined
above. It has been suggested that the true disease burden for
schistososomiasis may be several fold higher than previous
estimates [22], possibly making this infection the most important
NTD in SSA. In addition to S. haematobium and HIV co-infections
[76], S. mansoni and hookworm co-infections are common in SSA
and can lead to severe anemia [78–80]. A relationship has also
been proposed between schistosomiasis and malaria [81].
Among the other platyhelminth infections in SSA, paragonimi-
asis has been reported from eastern Nigeria and southwestern
Cameroon [82], although there are no estimates of the number of
cases. Cysticercosis caused by the pork tapeworm Taenia solium is a
major risk factor for epilepsy in SSA except in Muslim areas [83],
and it is hyperendemic in Burundi and elsewhere in eastern Africa
[84], southern Africa [85,86], and Cameroon [87]. It has been
suggested that cysticercosis may account for the presence of
subcutaneous nodules that erroneously have been linked with
onchocerciasis and may be responsible for seizures following mass
drug administration with anthelminthics [88]. However, the full
disease burden of cysticercosis in SSA remains largely unstudied.
Both taeniasis caused by the beef tapeworm Taenia saginata and
cystic echinococcosis are highly prevalent in East Africa, especially
in Ethiopia and Sudan [89,90].
Filarial infections (LF, onchocerciasis, loiasis, and
dracunculiasis). LF. Approximately 40% of the world’s 120
million cases of LF occur in SSA (approximately 46–51 million
cases) (Table 2) [3,7,25–28,91,92], with an estimated 382–394
million people at risk of infection, including 176 million children
[91,93]. In the 39 countries where LF occurs in SSA, the greatest
numbers of people at risk of infection live in Nigeria, followed by
DRC, Tanzania, Ethiopia, and Kenya (Table 3). All of the LF
cases in SSA are caused by Wuchereria bancrofti, which are
transmitted by a variety of culicine and anopheline mosquitoes
[92]. W. bancrofti infection produces a wide range of clinical
manifestations, including hydrocele and lymphoedema as the most
clinically obvious because of the associated disability,
disfigurement, and stigma [94]. Based on global estimates that
12.5% of LF infections are estimated to result in lymphedema and
20.8% in hydrocele [93], there are approximately 5 million cases
of lymphedema and 8 million cases of hydrocele in SSA. The
estimated 2.0 million DALYs lost annually from LF rank it third or
fourth behind hookworm and schistosomiasis (and possibly
ascariasis) as the most important NTD in SSA (Table 5). LF is
also associated with huge economic losses, impairing economic
activity up to 88% [9], and causes almost US$1 billion in annual
losses, mostly resulting from the disability linked to hydrocele in
men [95,96]. In addition to LF, endemic non-filarial elephantiasis
(podoconiosis) is widespread in SSA, with the areas of highest
prevalence in the highlands of East Africa as well as in some West
African countries [97].
Onchocerciasis. More than 99% of the estimated 37 million cases of
onchocerciasis occur in SSA (Table 2) [15], distributed in a wide
belt that extendsfromSenegalinthewesttoEthiopiainthe east and
from Mali in the north to Angola and Malawi in the south [15,29].
Based on rapid epidemiological mapping of onchocerciasis
(REMO), a non-invasive and practical tool for distribution and
disease prevalence, it is estimated that the mean infection rate
among the 19 countries targeted by the African Programme for
Onchocerciasis Control(APOC) is 38.2%with87 million persons at
riskforcontractingtheinfection[15]. In SSA, the clinical features of
the disease vary from the savanna form, more common in West
Africa and associated with high rates of blindness, to the rainforest
form more common in Central and East Africa in which high rates
of onchocera skin disease (OSD) are characterized by severe
pruritus and disfigurement (also known as ‘‘troublesome itching’’)
[29]. In hyperendemic communities where the prevalence of
onchocerciasis exceeds 60%, blindness can occur in 10% or more of
some savanna populations, while OSD can affect more than 50% of
some rainforest communities [29]. Both forms are linked with high
disability as well as severe socioeconomic consequences. It is
estimated that 40% of the DALYs lost from onchocerciasis result
from blindness, while 60% are from OSD [29].
Loiasis. The African eyeworm has a high prevalence in rainforest
areas of low socioeconomic status and in some savanna regions
[32]. The infection is common in Angola, Benin, Cameroon,
Central African Republic, Congo, DRC, Equatorial Guinea,
Gabon, Nigeria, and Sudan [32]. Loa infection is associated with
Calabar swellings that result from filarial migrations in the
subcutaneous tissues, but the greatest concern about the infection
is the risk associated with ivermectin treatments for onchocerciasis
co-infections [98]. Angola, Cameroon, and DRC exhibit the
highest rates of co-endemicity and consequently, represent the
highest risk areas for serious adverse events during mass drug
administration [98]. A rapid assessment method based on a
clinical history of eyeworm infection and known as RAPLOA is in
use to evaluate local prevalence of loiasis, as well as a spatial model
based on environmental factors [98].
Dracunculiasis. All of the world’s cases of dracunculiasis occur in
SSA. In 2007, only 9,585 cases were reported (Table 2), a 99%
reduction in the number of cases since most endemic countries
began to report using village-based surveillance systems [36].
During 2007, Sudan (5,815) and Ghana (3,358) accounted for
96% of the total cases, with the remainder in Mali, Niger, and
Nigeria (Table 3) [36]. Mali experienced two unexpected
outbreaks during this period [99].
Protozoan Infections
HAT and leishmaniasis are the major protozoan infections in
SSA, accounting for almost 2 million DALYs lost annually
Table 6. Ranking by Disease Burden (DALYs) and Comparison
of Total NTDs with HIV/AIDS, Tuberculosis, and Malaria.
Disease Disease Burden in SSA (DALYs) Reference
HIV/AIDS 64.0 million [45]
Malaria 40.9 million [45]
NTDs 8.6–21.2 million
Helminth infections 5.4–18.3 million
Tuberculosis 9.3 million [45]
doi:10.1371/journal.pntd.0000412.t006
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SSA, but there are few estimates of their prevalence, incidence, or
disease burden (Table 4).
HAT. Through stepped-up public health control efforts over
the last decade, the major endemic countries in SSA have made
great strides in reducing the number of cases of HAT from
300,000–500,000 cases to approximately 50,000–70,000 cases,
along with 17,000 new cases occurring annually (Table 2) [39].
Approximately 90% of the cases are caused by Trypanosoma brucei
gambiense, a cause of chronic Gambian HAT [100], with most of
the new cases occurring in DRC (10,369 new cases in 2004),
followed by Angola, Sudan, Republic of Congo, and Central
African Republic (Table 3). The major reductions in Gambian
HAT are a result of interruptions in conflict [39]. Despite these
gains, outbreaks of Gambian HAT occurred in Angola, DRC, and
Sudan in 2005 [40]. HAT caused by T. b. rhodesiense accounts for
the remaining cases of HAT in SSA, with most of the new cases
occurring in Malawi, Uganda, and the United Republic of
Tanzania [39]. Rhodesian HAT is a zoonosis transmitted from
cattle and other mammals, which produces an acute and
fulminating sleeping sickness [39,100]. Populations in the age
group between 15 and 45 years and living in remote rural areas
are considered especially vulnerable to both forms of HAT [39].
Currently, the only country with both Gambian and Rhodesian
HAT is the nation of Uganda, but to date each focus is
geographically separated [101].
Leishmaniasis. Both visceral and cutaneous forms occur in
SSA, with the former producing serious disease associated with
high mortality. Most of the cases of visceral leishmaniasis (VL)
occur in the Horn of Africa, i.e., the East African countries of
Sudan, Eritrea, Ethiopia, Kenya, and Somalia [43], with most of
them caused by Leishmania donovani (Table 3), although some cases
are caused by L. infantum[42]. Because many cases occur in areas of
conflict and forced human migrations, the exact number occurring
in East Africa is not well established, nor is the disease burden.
During the 1980s, an estimated 100,000 people died as a result of
VL epidemics [42]. In Sudan alone, as a result of long-standing
civil war, hundreds of thousands of cases occurred with death rates
exceeding 50% in some areas [43]. Today, the continuing
widespread conflict in these countries has destroyed housing and
health care infrastructure, and the resultant forced migrations to
endemic areas still promote the emergence of VL [42]. Adding to
the problem is widespread malnutrition as a result of drought,
which increases susceptibility to infection and contributes to the
progression of disease [42]. The highest incidence of the disease
occurs in Sudan (especially near part of its border with Ethiopia,
where 15,000–20,000 new cases occur annually), followed by
Ethiopia with approximately 4,000 new cases (Table 2) [41,43].
The Pokot territory of Kenya and Uganda is also endemic [102].
In these areas VL is considered primarily an anthroponotic
infection [103,104]. VL is also an important opportunistic
infection associated with HIV/AIDS in East Africa [41],
especially in the Tigray region on the Sudan–Eritrea border
where soldiers and seasonal workers sleep outdoors in sandfly-
infested areas [43]. Cutaneous leishmaniasis caused by infection
with Leishmania major is also endemic in parts of SSA including
West Africa, where there has been a major increase in the number
of cases near Ougadougou, the Burkina Faso capital [41], and in
Sudanese refugee camps in Chad [43].
Amebiasis. The epidemiology of amebiasis is poorly
understood in SSA because few studies differentiate true
infection caused by Entamoeba histolytica versus infection resulting
from the non-pathogenic variant, E. dispar[105]. Based on
seroprevalence studies in Sudan, Cote d’Ivoire, and South
Africa, however, the distribution of amebiasis is believed to be
widespread [105]. Amebiasis has also been reported from Nigeria
[106]. In South Africa it has been observed that invasive E.
histolytica infection is associated more commonly with amebic liver
abscess than colitis [105].
Toxoplasmosis. The study of toxoplasmosis has also been
neglected in SSA, although investigations conducted in Sudan
[107] and Burkina Faso [108] indicate a high seroprevalence
among pregnant women, while studies in West Africa [109]
indicate a high seroprevalence in children. Toxoplasmosis is
considered a common AIDS defining illness in Ethiopia [110],
Nigeria [111], and presumably elsewhere in SSA.
Bacterial Infections
The major bacterial NTDs are trachoma, mycobacterial
infections, tick-borne zoonoses, typhoid fever and non-typhoidal
salmonellosis, and yaws. With the exception of trachoma, data on
the regional prevalence and/or incidence of these diseases area
severely lacking, as are disease burden estimates in DALYs
(Table 4).
Trachoma. Trachoma is the leading cause of infectious and
preventable blindness worldwide [112–114], and the most
important bacterial infection in SSA. Of the 63 million cases of
active trachoma globally (although some estimates indicate 84
million cases worldwide), 48% occur in SSA (30 million) (Table 2)
[115]. Nearly half of the global disease burden of active trachoma
and a quarter of end-stage trichiasis are concentrated in ten
countries alone, with six of these located in SSA [116].
Geographically, trachoma is distributed mainly in the savannah
areas of East and Central Africa and the Sahel of West Africa
[112]. Ethiopia has the largest number of cases (10.2 million),
followed by Sudan (3.6 million) and Tanzania, Kenya, and Niger
(2.0–2.1 million each) (Table 3). Approximately one-half of the 2.3
million global trachoma disease burden in DALYs is attributed to
SSA (Table 4). Like the other NTDs, trachoma is sustained in a
setting of poverty. Additional risk factors for trachoma
transmission include crowding and household clustering,
insufficient access to water, poor sanitation and facial hygiene,
and young children as the reservoir of infection [115]. For
instance, in southern Sudan, where more than 90% of the people
live on less than US$1 per day, and only 27% have access to water
and 16% to improved sanitation conditions, the prevalence of
trachoma is ranked among the highest worldwide [117,118].
Hyper-endemic areas in SSA have been found to have an earlier
age of onset of trichiasis [118], while women are two to four times
more likely to have trichiasis due to increased exposure to young
children [116,119]. Dry zones with limited water accessibility and
hot lowlands (altitude ,3,000 m) with dense fly populations also
promote transmission [112,120]. Post-conflict conditions, namely
in Sudan and Rwanda, have been assessed, but with differing
conclusions on their impact on the prevalence of blindness. In
southern Sudan, the prevalence of blindness (4.1%) is four times
greater than that of the rest of Africa [121].
Mycobacterial infections. Buruli ulcer. Of the estimated
7,000 cases of Buruli ulcer reported annually [38], more than
4,000 cases occur in SSA (Table 2), with the largest number
reported from the West African countries of Cote d’Ivoire
(approximately 2,000 cases) and Benin and Ghana (reporting
approximately 1,000 cases each) (Table 3) [37]. The greatest risk
factors for acquiring Buruli ulcer include residing in an endemic
area, close proximity to specific bodies of water, and age less than
15 years [37,38].
Leprosy. In Africa, the number of new cases of leprosy has
declined every year since 2001 [35]. At the beginning of 2008,
www.plosntds.org 6 August 2009 | Volume 3 | Issue 8 | e412approximately 30,055 cases of leprosy were registered in Africa
with 31,037 new cases in 2007 (Table 2) [35]. These represent
approximately 14% and 12% of the global prevalence and new
cases, respectively (Table 2). In SSA, the highest registered
prevalence occurs in DRC (6,502 cases), followed by Nigeria
(5,381), Ethiopia (4,611), and Mozambique (1,830) (Table 3) [35].
Similarly, in 2007, the largest number of new cases occured in
DRC (8,820), Nigeria (46,650), Ethiopia (4,187), and Mozambique
(2,610) [35].
Bovine tuberculosis. Tuberculosis is a major opportunistic infection
among HIV-infected populations in SSA and it is estimated that
70% (6 million) of the people co-infected with tuberculosis and HIV
live in SSA [122]. The proportion of African tuberculosis due to
Mycobacterium bovis is unknown [123], although it is estimated that
approximately 50% of African cattle live in countries without
control measures for the disease [122]. In SSA, bovine tuberculosis
frequently passes from livestock to wildlife, while human popula-
tionsbecomeinfectedthroughtheconsumptionofrawmilkand raw
meat (including bushmeat) [122]. The prevalence and incidence of
bovine tuberculosis in SSA has not been established.
Tick-borne zoonoses. Tick-borne relapsing fever (TBRF). TBRF
is an acute febrile illness caused by the spirochaete Borrelia crocidurae
and transmitted by an Ornithodoros tick [124]. If left untreated,
patients develop severe relapsing remitting fever, and in some
parts of Senegal and elsewhere in West Africa this infection is
second only to malaria as the most common cause of outpatient
visits [124]. However, detailed information on the precise
incidence and distribution of TBRF in SSA is lacking because
the disease is underdiagnosed and medical personnel have
inadequate awareness of this infection and frequently confuse it
with malaria [124].
African tick-bite fever. African tick-bite fever is a spotted fever group
rickettsiosis caused by Rickettsia africae and transmitted by Amblyomma
ticks [125]. It is known to be endemic in Zimbabwe and South
Africa, although based on serologic surveys the infection also occurs
elsewhere in SSA [125,126]. Infection with R. africae is common in
travelers returning to Europe and North America [125,126].
Salmonella and other enteric infections. Although well-
publicized outbreaks of typhoid fever (Salmonella typhi infection)
have been reported from Kenya [127], the overall incidence of
culture-proven typhoid fever may be lower than 1/100,000 person
years [128]. In SSA, S. typhi infection has been noted to occur in
association with schistosome infections [129]. Of concern is the
emergence of drug-resistant typhoid fever [129,130]. Similarly,
nontyphoidal salmonella (NTS) infection and bacteremia (some of
which are caused by drug-resistant strains) is emerging as an
important opportunistic infection in individuals infected with HIV
and in children [131,132]. In Malawi and elsewhere in SSA, NTS
bacteremia typically presents in children less than 3 years of age,
especially those with coincident anemia, malaria, malnutrition,
and HIV infection [131–133]. Among adults, NTS is most
commonly associated with advanced HIV disease [131]. In
Malawi, approximately 75% of the cases of NTS are associated
with Salmonella enterica serovar Typhimrium and 21% with S. enterica
serovar Enteritidis [131,132]. Campylobacter jejuni has emerged as a
common cause of enteritis in Nigeria [134].
Yaws. Yaws is a skin disease caused by Treponema pallidum,
subspecies pertennae, and Africa has the highest concentration of the
disease [135]. Africa’s indigenous pygmies are disproportionately
affected, although there are no published estimates of the disease.
Viral Infections
Arboviral infections, including yellow fever, dengue, Chikungu-
nya and Rift Valley fever [136], and rabies stand out as the most
important viral NTDs. As with the bacterial infections, there are
few estimates of their incidence or disease burden.
Arobviral infections. Approximately 90% of the world’s
200,000 cases of yellow fever (and 30,000 deaths) occur in SSA
[33]. Especially in Francophone West Africa, transmission of
yellow fever is maintained by high densities of Aedes aegypti
mosquitoes in close proximity to unvaccinated human populations
[33]. Yellow fever is underreported, although a laboratory network
in the endemic countries of West and Central Africa was
established in 2002 in order to strengthen capacity for diagnosis
[34]. In 2006, cases of yellow fever were reported in Cameroon,
Central African Republic, Cote d’Ivoire, Ghana Guinea, Mali,
and Togo [34]. Since 2000, four urban outbreaks have occurred in
West Africa, including a 2001 outbreak in Abidjan, Cote d’Ivoire,
that required the immunization of 2.6 million people in 12 days
[137]. All four dengue viral types have been reported from Africa,
although to date no epidemic of dengue hemorrhagic fever has
been reported [138]. Epidemics of Chikungunya fever have also
been reported in Angola, Burundi, Cameroon, CAR, Kenya,
Namibia, Nigeria, Senegal, South Africa, Tanzania, Uganda, and
Zimbabwe [125]. Rift Valley fever is a bunyavirus infection
transmitted by mosquitoes, which is a problem not only for
humans but also for sheep, goats, and cattle. Epidemics and
epizootics occur after periods of heavy rains [139]. Epizootics are
closely linked to excess rainfall resulting from El Nin ˜o and sea
surface temperature anomalies in the Indian and Pacific Oceans
[139].
Rabies. Following India, the greatest number of cases of
human rabies transmitted from dogs occurs in SSA [140]. In
Limpopo Province (South Africa) alone, 100 cases occurred in
2006 [140]. There are two distinct biotypes in southern Africa, a
canid virus and a mongoose virus [141].
Concluding Statement: Disease Assessment and
Control Priorities
Overall, it should be noted that the estimates of infection
prevalence and morbidity provided here are, in many cases, based
on limited data. Moreover, there is often spatial heterogeneity of
the NTDs within large geographic units, i.e., at the regional or
country level. This is particularly true for most of the vector-borne
NTDs. From the analysis reported here, two nations stand out has
having the largest number of NTD cases and possibly disease
burden. Nigeria is estimated to have the highest prevalence of
helminth infections such as hookworm, schistosomiasis, ascariasis,
trichuriasis, and LF in SSA, as well as the second highest registered
prevalence of leprosy (Table 3). In addition, arboviral and other
zoonotic infections are common in Nigeria, including yellow fever,
rabies, and toxoplasmosis [134], while Buruli ulcer is found in the
southern and southeastern areas of the country [142]. Similarly,
DRC exhibits the highest prevalence of HAT and leprosy in SSA,
as well as the second highest prevalence of hookworm infection
and trichuriasis (and possibly LF), and the third highest prevalence
of schistosomiasis and ascariasis (Table 3). Together, Nigeria and
DRC account for approximately one-third of the helminth
infections and leprosy in SSA, as well as up to one-fifth of the
cases of HAT. A targeted approach for these two countries could
make a substantial impact on Africa’s overall NTD disease burden.
The information presented here indicates that helminth
infections, especially the three major STH infections, schistoso-
miasis, LF, and onchocerciasis, account for up to 85% of the
disease burden caused by NTDs in SSA (Table 6). Given that
NTDs may be responsible for as much as one-half and one-third of
the region’s malaria and HIV/AIDS disease burden, respectively,
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experts, health ministries, and global policy makers. In addition,
based on revised estimates for schistosomiasis that fully consider
the morbidities of chronic infection including effects on anemia,
malnutrition, growth stunting, and diminished child development
[22,23], and the observation that many of these same sequelae
occur for STH and other helminth infections [4,5,50,51,57–61],
the possibility remains that maternal and child helminthiases may
increase even further in their disease control priority rankings.
There is an urgent need for better direct or indirect methods of
estimating the disease burden for the NTDs and other conditions.
Disease burden estimates for the major helminthiases and other
NTDs (based on DALYs as the major metric) are currently being
re-evaluated in an initiative led by the Institute for Health Metrics
and Evaluation at the University of Washington and supported by
the Bill & Melinda Gates Foundation [143–145]. Another high
priority is to begin obtaining prevalence, incidence, and disease
burden estimates for many of the non-helminth NTDs. Amebiasis
and toxoplasmosis stand out as both common and serious
protozoan infections for which we have very little information.
Similarly, the data available for human Salmonella and tick-borne
zoonotic bacterial infections are minimal even though some
reports suggest they be enormously important. Stepped-up
surveillance measures for some of Africa’s arboviral infections
may provide timely and useful data in the coming years. A full
analysis of all Africa’s NTDs is an essential step towards
prioritizing these conditions relative to ongoing HIV/AIDS and
malaria control efforts supported by private foundations and the
Group of Eight nations.
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